Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03113643
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03113643 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on NCT03113643 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03113643 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Azacitidine; SL-401; Venetoclax
- Arms
- SL-401+ Azacitidine · Experimental
- SL-401+ Azacitidine + Venetoclax · Experimental
- Enrollment
- 72 (estimated)
- Primary outcomes
- Maximum Tolerated Dose
- Sponsor
- Dana-Farber Cancer Institute with Stemline Therapeutics, Inc.
- Start
- Jun 26, 2017
- Primary completion
- Sep 15, 2021
- Results posted
- No
- Registry record
- NCT03113643 · updated Jun 17, 2026
Publications
linked from the registry- Lane AA, Luskin MR, Keating J, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen TT, Galinsky I, Eberly-Puleo A, Daver N, Jain N, Garcia-Manero G, Kantarjian H, Konopleva MY, Stein A, Pemmaraju N. Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm. Blood. 2026 Oct 29;148(18):2229-2238. doi: 10.1182/blood.2026033906. PubMed 42413008
- Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 Feb 13;8(3):591-602. doi: 10.1182/bloodadvances.2023011721. PubMed 38052038
- Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. No abstract available. PubMed 33795208